DR. TERRY W. HOOD, M.D.

Plain English
This study looked at a program called TIMELY, which aimed to boost the number of minority patients referred to lupus clinical trials by training healthcare providers and community health workers. After participating in the program, knowledge about clinical trials increased significantly for providers and community health workers, with providers showing lasting improvements in their confidence and willingness to refer patients. This is important because it could help ensure that more diverse patients are included in lupus research, improving treatment options for everyone. Who this helps: This benefits patients with lupus, especially those from minority backgrounds.

Plain English
This study focused on understanding food protein-induced enterocolitis syndrome (FPIES), a serious allergic reaction mainly affecting infants, by collecting data from multiple medical centers in the United States. Researchers created a registry that tracks things like when symptoms start, what foods trigger reactions, and how many patients develop different types of allergies. The goal is to improve patient care and outcomes by better understanding FPIES and identifying key factors related to the condition. Who this helps: This helps patients with FPIES and their doctors by providing essential information for diagnosis and treatment.

Plain English
This study looked at the safety and effectiveness of a new drug, KB-0742, for patients with advanced adenoid cystic carcinoma (ACC), a rare type of cancer. Researchers found that the drug was generally well tolerated, with 56% of patients experiencing stable disease for at least six months, although no significant tumor shrinkage was observed. This is important because it offers a potential treatment option for patients who currently have very few choices for managing this cancer. Who this helps: This helps patients with advanced adenoid cystic carcinoma.

Plain English
This study looked at ways to improve the manufacturing process for CAR-T cell therapies, which are effective in treating certain types of leukemia and lymphoma, but face challenges in being produced at scale. Researchers found that starting the perfusion process earlier (after 48 hours instead of 96) and increasing the perfusion rate led to a greater production of CAR-T cells, achieving over 21 billion cells per milliliter in just 7 days. This matters because it can make CAR-T therapies more accessible to patients by improving the efficiency and quality of the manufacturing process. Who this helps: This helps patients with leukemia and lymphoma seeking effective treatment options.

Plain English
This study looked at ways to grow CAR-T cells, a type of immune cell used in cancer treatment, more quickly and cost-effectively without using animal or human serum. The researchers found that by optimizing the growth conditions, they improved cell yields by 4.5 times and reduced the time needed to produce these cells by over 50%, achieving high cell densities while using less growth medium. This matters because it can make CAR-T cell therapies more efficient and safer for patients. Who this helps: Patients receiving CAR-T cell therapy.

Plain English
Researchers focused on reducing the number of blood tests for newborn jaundice in a community hospital nursery, aiming to cut the number of tests given to babies in half, from 30.6% to 15.3%. They implemented several strategies, including following new guidelines and improving communication among staff, which successfully reduced the percentage of newborns needing these tests to 17.3% and lowered the rate of phototherapy treatment from 7.6% to 5.2%. This matters because fewer tests mean less discomfort for babies and a more efficient use of hospital resources. Who this helps: This helps newborns and their families by reducing unnecessary procedures in the hospital.

Plain English
This study looked at what occupational therapy (OT) educators in the United States think about incorporating climate change and environmental issues into their teaching programs. It found that while most educators see climate change as important to address, many face challenges like crowded curricula and uncertainty about how to connect these topics to OT. The results highlight a need for better educational resources to help integrate climate-related content into OT training. Who this helps: This benefits occupational therapy students and practitioners by preparing them to consider environmental factors in their work.

Plain English
This study looked at how to make CAR-T cell therapies more effectively by testing different factors in their production process. Researchers found that using a single activation step and shortening the preparation time significantly boosted the number and quality of CAR-T cells, achieving a threefold increase in cell yield and a 30% decrease in exhaustion markers compared to other methods. These improvements mean that CAR-T therapies can become more reliable and accessible for patients with challenging blood cancers. Who this helps: This benefits patients with relapsed and refractory blood cancers by improving their treatment options.

Plain English
Researchers studied the composition of the giant exoplanet WASP-76b, focusing on 14 key elements that are important for understanding how such planets form. They discovered that nickel was particularly abundant, indicating that the planet may have gained material from a dense core during its development. Their results also showed a clear change in the presence of certain minerals at a temperature of 1,550 degrees Kelvin, illustrating how temperature affects what elements can be found in the planet’s atmosphere. Who this helps: This research benefits astronomers and scientists studying the formation and characteristics of exoplanets.

Plain English
This study looked at how the immune system interacts with acute myeloid leukemia (AML) and how this affects patients' responses to treatments like chemotherapy and immunotherapy. Researchers analyzed 442 samples from both children and adults, finding that certain immune profiles could help predict which patients would struggle against chemotherapy and which would benefit from a specific treatment called flotetuzumab. The findings highlight the importance of understanding immune characteristics to tailor treatments for AML based on individual patient needs. Who this helps: This research benefits patients with acute myeloid leukemia by guiding more personalized treatment approaches.

Plain English
This study looked at patients with acute myeloid leukemia (AML) who have specific changes in a gene called TP53. Researchers found that around 37% to 46% of these patients have TP53 mutations, which are linked to poorer outcomes. Notably, 47% of patients with these mutations responded very well to a new treatment called flotetuzumab, achieving complete remission, with those who responded living an average of over 10 months longer. Who this helps: This is beneficial for patients with AML who have TP53 mutations, helping inform treatment options.

Plain English
This study focused on creating a new type of building block for peptide nucleic acids (PNAs) that includes a special bond called a disulfide bond, which can break down in biological conditions. The researchers successfully developed a disulfide Fmoc monomer that can be used in PNAs, showing that the new structure forms stable duplexes with other PNAs and can be cleaved by reducing agents. This is important because it could improve the delivery of therapeutic PNA constructs inside cells. Who this helps: This benefits researchers and doctors working on gene therapies and diagnostics.

Plain English
This study focused on understanding the environment around tumors in patients with metastatic osteosarcoma, a common bone cancer in young people. Researchers found that in metastatic tumors, T cells, which help fight cancer, were pushed out to the edges, and there were problems with blood vessels that supply the tumors. Specifically, they observed that as the blood vessel dysfunction increased, the number of T cells decreased, which suggests that improving the blood supply might help bring more immune cells into the tumors. Who this helps: This research benefits patients with metastatic osteosarcoma by highlighting possible new treatment targets that could enhance immune response.

Plain English
This study looked at how the Prosigna gene expression test can predict how well premenopausal women with high-risk breast cancer will respond to certain chemotherapy treatments, specifically cyclophosphamide-based ones. Out of 460 women analyzed, the test showed that those with basal-like and luminal B cancer types had a much lower risk of cancer returning when treated with cyclophamide compared to those with other cancer types, while patients with basal-like cancer had a hazard ratio of 0.14, meaning they were significantly better off. Understanding these results can help doctors tailor treatments to patients based on their specific cancer type. Who this helps: This benefits patients with high-risk breast cancer and their doctors in choosing effective treatment options.

Plain English
Researchers studied cancer cells to find out which genes are vital for cancer survival and how they interact, using a method called RNA interference (RNAi) on nearly 8,000 genes across 398 types of cancer. They identified specific "dependency" genes that cancer cells rely on, which could lead to new treatment options. This is important because it helps uncover potential targets for therapies aimed at cancers where certain tumor-suppressing genes are not working properly. Who this helps: This benefits patients with cancer by providing new avenues for treatment options.

Plain English
This study looked at how different designs of synthetic materials called neural scaffolds can help damaged nerves heal after injuries. Researchers created various fiber shapes and sizes, finding that certain designs encouraged better nerve cell growth. Specifically, they observed improved movement and alignment of nerve cells when using these new scaffolds, which can significantly speed up healing and recovery. Who this helps: This research benefits patients with peripheral nerve injuries seeking effective repair options.

Plain English
This study focused on developing new drugs that specifically target a protein called anaplastic lymphoma kinase (ALK), which is involved in certain cancers like anaplastic large cell lymphoma and non-small cell lung cancer. The researchers created and tested new inhibitors of ALK, showing they were effective in laboratory mice with anaplastic large cell lymphoma. These findings are important because they could lead to better treatments for patients with cancers driven by ALK. Who this helps: This helps cancer patients, particularly those with anaplastic large cell lymphoma and non-small cell lung cancer.

Plain English
Researchers studied a new class of drugs designed to block proteins called TRKs, which are linked to various cancers. They discovered that one specific drug, (R)-2-phenylpyrrolidine-substituted imidazopyridazines, effectively reduced tumors in rats, showing strong potential for treating cancer. This is significant because targeting TRKs can potentially improve outcomes for patients with cancers like colorectal, thyroid, and lung cancers. Who this helps: Patients with certain types of cancer.

Plain English
This study looked at prefilled medical devices designed for delivering drugs without needing healthcare workers to give the injections. The research found that these devices help reduce the risk of needle-related injuries and make patients more comfortable, especially in areas like endocrine diseases and emergency medicine. Using these devices also saves money and is easier for both patients and doctors, which can lead to better care. Who this helps: This helps patients, doctors, and healthcare systems.

Plain English
This study examined how two targeted cancer drugs, imatinib and nilotinib, behave inside living cells, focusing on their accumulation in specific cell compartments called lysosomes. The researchers found that both drugs concentrated more than 1,000 times in lysosomes, and the presence of another drug, chloroquine, significantly reduced imatinib's retention in these compartments by more than ten times. Understanding how these drugs are taken up and processed in cells is important because it can lead to improved treatment effectiveness for patients with chronic myelogenous leukemia. Who this helps: Patients with chronic myelogenous leukemia.

Plain English
Researchers studied new compounds that can inhibit the Wnt signaling pathway, which is important for regulating cell processes and is linked to cancer growth. They found a specific type of compound, called [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles, that effectively blocks the activity of two proteins, tankyrases 1 and 2, which play a role in this pathway. These findings show promise in developing new treatments for cancers driven by Wnt signaling. Who this helps: This benefits cancer patients by potentially leading to new therapies.

Plain English
This study focused on developing a new drug called GNF-5837, which targets specific proteins involved in cancer growth. In tests with mice, GNF-5837 effectively slowed tumor growth in models that had these proteins. This finding is important because it shows promise for treating different types of cancer linked to these proteins, potentially leading to better treatments in the future. Who this helps: Patients with certain types of cancer.

Plain English
This study looked at a new tool, called the Graded Prognostic Assessment (GPA), to predict survival in patients with brain metastases based on factors like age and number of brain tumors. Researchers analyzed information from nearly 2,000 patients, and found that those with the highest GPA scores (3.5-4.0) had a median survival of about 11 months, while those with the lowest scores (0-1.0) had a median survival of only 2.6 months. This tool helps doctors make better treatment decisions by clearly showing that not all patients with brain metastases have the same outlook. Who this helps: This helps patients with brain tumors and their doctors by providing a clearer view of expected survival times.

Plain English
This study examined the differences between lead-resistant and lead-sensitive strains of Staphylococcus aureus, a type of bacteria. Researchers found five strains that could resist high levels of lead, able to handle about 600 times more lead than the sensitive strains. The resistant strains not only bound lead but also stored it inside them in a stable form, which could be important for understanding how these bacteria survive in contaminated environments. Who this helps: This helps doctors and researchers studying bacterial infections and resistance.

Plain English
Researchers studied how certain brain receptor sites in the hippocampus, which are crucial for communication between nerve cells, are affected in patients with temporal lobe epilepsy who do not respond to medication. They found that a specific type of receptor linked to excitatory signals was reduced by 35 to 70%, while another excitatory receptor increased by 20 to 110% in certain areas of the brain. Additionally, inhibitory receptor binding decreased by 20 to 60% in some regions, indicating a significant imbalance in brain signaling that could be contributing to epilepsy. Who this helps: This research benefits patients with temporal lobe epilepsy and their doctors by providing insights that could lead to better treatment strategies.

Plain English
This study looked at how different durations of low-intensity exercise affect fats in the blood, specifically lipoproteins. Researchers tested 22 young, healthy male runners who exercised for either 15, 30, or 45 minutes. They found that after 30 minutes of exercise, participants had lower levels of good cholesterol (HDL-C) 24 hours later compared to those who exercised for 45 minutes (46.41 mg/dl vs. 53.34 mg/dl). This matters because understanding how exercise duration impacts blood fats could help in personalizing exercise recommendations for better heart health. Who this helps: Patients and fitness trainers looking to optimize exercise routines for heart health.